Eagle Asset Management Inc. decreased its position in FibroGen Inc (NASDAQ:FGEN) by 1.3% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 818,865 shares of the biopharmaceutical company’s stock after selling 10,573 shares during the quarter. Eagle Asset Management Inc. owned 1.00% of FibroGen worth $39,034,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also recently bought and sold shares of FGEN. State of Wisconsin Investment Board lifted its position in FibroGen by 50.0% during the 4th quarter. State of Wisconsin Investment Board now owns 66,000 shares of the biopharmaceutical company’s stock valued at $3,128,000 after purchasing an additional 22,000 shares during the period. BBR Partners LLC increased its stake in shares of FibroGen by 18.0% in the 4th quarter. BBR Partners LLC now owns 6,556 shares of the biopharmaceutical company’s stock valued at $311,000 after acquiring an additional 1,000 shares during the last quarter. BHK Investment Advisors LLC bought a new stake in shares of FibroGen in the 4th quarter valued at about $654,000. The Manufacturers Life Insurance Company increased its stake in shares of FibroGen by 5.7% in the 4th quarter. The Manufacturers Life Insurance Company now owns 53,197 shares of the biopharmaceutical company’s stock valued at $2,521,000 after acquiring an additional 2,872 shares during the last quarter. Finally, First Trust Advisors LP increased its stake in shares of FibroGen by 1,058.4% in the 4th quarter. First Trust Advisors LP now owns 776,640 shares of the biopharmaceutical company’s stock valued at $36,813,000 after acquiring an additional 709,598 shares during the last quarter. 59.24% of the stock is currently owned by institutional investors and hedge funds.
Shares of FibroGen Inc (FGEN) traded up $1.30 during trading on Friday, reaching $57.50. The company’s stock had a trading volume of 362,992 shares, compared to its average volume of 594,103. FibroGen Inc has a fifty-two week low of $22.75 and a fifty-two week high of $63.00. The company has a debt-to-equity ratio of 0.16, a current ratio of 10.83 and a quick ratio of 10.83.
A number of research firms recently issued reports on FGEN. Mizuho reissued a “hold” rating and set a $61.00 target price on shares of FibroGen in a research note on Thursday, November 9th. ValuEngine cut shares of FibroGen from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. Finally, BidaskClub cut shares of FibroGen from a “hold” rating to a “sell” rating in a research note on Thursday, December 7th. Four analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $65.67.
In other FibroGen news, CEO Thomas B. Neff sold 39,636 shares of FibroGen stock in a transaction dated Friday, February 23rd. The stock was sold at an average price of $56.66, for a total value of $2,245,775.76. Following the transaction, the chief executive officer now owns 2,955,614 shares in the company, valued at $167,465,089.24. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Pat Cotroneo sold 49,500 shares of FibroGen stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $55.96, for a total value of $2,770,020.00. Following the completion of the transaction, the vice president now owns 207,392 shares in the company, valued at approximately $11,605,656.32. The disclosure for this sale can be found here. Insiders have sold 392,653 shares of company stock valued at $20,109,362 in the last three months. Insiders own 13.60% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “FibroGen Inc (NASDAQ:FGEN) Position Lowered by Eagle Asset Management Inc.” was first published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright and trademark law. The original version of this piece of content can be viewed at https://ledgergazette.com/2018/02/25/fibrogen-inc-fgen-position-trimmed-by-eagle-asset-management-inc.html.
FibroGen Company Profile
FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.